Stimcell Energetics Inc.
AI Executive Summary
AI-powered analysis of 10-K filing content
Stimcell Energetics (formerly Cell MedX Corp.) remains a pre-revenue biotech shell-like company with no product sales for years, widening net losses (up 58.1% to $895,375), and disclosed material weaknesses in internal controls. A recent 1-for-15 reverse stock split and corporate name change suggest attempts to reposition the company, but underlying business fundamentals—including lack of FDA approval and zero revenue-generating activity—remain unchanged or worsened.
Red Flags Detected (8)
No revenue generated in FY2026 or FY2025 despite years of R&D on eBalance Technology
Net loss increased 58.1% year-over-year to $895,375
Disclosure controls and internal controls over financial reporting deemed not effective due to lack of segregation of duties
5 more red flags detected
Key Takeaways
Company has no commercialized products or revenue despite over a decade since technology acquisition (2014)
Persistent internal control weaknesses due to lack of segregation of duties raise financial reporting reliability concerns
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.